Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bupropion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 5/20 | 1.00 |
| ▸ | CHRNG | P07510 | 5/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 5/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 5/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 5/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 5/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 5/20 | 1.00 |
| ▸ | CHRND | Q07001 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | ITGA5 | P08648 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bupropion SCHEMBL60314 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL30679332 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL38777 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29424575 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29354885 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL300444 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL5608195 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL636116 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL4972526 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL31748783 | 0.98 | SLC6A2 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228845-A1 | COMBINATION DOSAGE FORMS AND ADMINISTRATION THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-07-17 | — | — | US | claimed |
| US-20240293342-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS, INC. (US) | 2024-09-05 | — | — | US | claimed |
| US-20240277635-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | claimed |
| US-11786488-B2 | Dosage forms and methods for enantiomerically enriched or pure bupropion | AXSOME THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | claimed |
| US-20230248669-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-10 | — | — | US | claimed |
| US-20230248668-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-10 | — | — | US | claimed |
| US-11433035-B2 | Dosage forms and methods for enantiomerically enriched or pure bupropion | AXSOME THERAPEUTICS, INC. (US) | 2022-09-06 | — | — | US | claimed |
| US-20220193011-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-06-23 | — | — | US | claimed |
| US-20260014142-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014142-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| CN-120827545-A | Dosage forms and methods for enantiomerically enriched or pure bupropion | 艾克萨姆治疗公司 | 2025-10-24 | — | — | CN | disclosed |
| US-20250127732-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-04-24 | — | — | US | disclosed |
| US-20240417368-A1 | METHODS OF TREATING NEUROLOGICAL AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION | AXSOME THERAPEUTICS, INC. | 2024-12-19 | — | — | US | disclosed |
| US-12102606-B2 | Dosage forms and methods for enantiomerically enriched or pure bupropion | AXSOME THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20190216801-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190216800-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20180015042-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY | INTAS PHARMACEUTICALS LTD. (IN) | 2018-01-18 | — | — | US | disclosed |
| EP-2527314-B1 | Process for preparation of phenyl carbamate derivatives | BIO-PHARM SOLUTIONS CO LTD (KR) | 2017-10-04 | — | — | EP | disclosed |
| US-9732031-B2 | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion | DEUTERX, LLC (US) | 2017-08-15 | — | — | US | disclosed |
| WO-2012118562-A1 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION, ADHD AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS EMPLOYING NOVEL BUPROPION COMPOUNDS, AND METHODS FOR PRODUCTION AND USE OF NOVEL BUPROPION COMPOUNDS AND FORMULATIONS | RHINE PHARMACEUTICALS, LLC (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248668-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A5, GABBR1 | SLC6A3 12/4885SLC6A2 6/4885CHRNA1 208/4885 |
| US-20230248669-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A5, CYP2B6 | SLC6A3 12/4885SLC6A2 7/4885CHRNA1 213/4885 |
| US-20260014142-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A43, OPRD1 | SLC6A3 13/4885SLC6A2 11/4885CHRNA1 183/4885 |
| US-20240417368-A1 | METHODS OF TREATING NEUROLOGICAL AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION | DBH, HSD3B1, HSD3B2 | SLC6A3 10/4885SLC6A2 38/4885CHRNA1 521/4885 |
| US-20250127732-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A5, CYP2B6 | SLC6A3 12/4885SLC6A2 7/4885CHRNA1 213/4885 |
| US-20240277635-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A5, CYP2B6 | SLC6A3 12/4885SLC6A2 7/4885CHRNA1 213/4885 |
| US-20180015042-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY | MC4R, GLP1R, GPR119 | SLC6A3 118/4885SLC6A2 61/4885CHRNA1 180/4885 |
| US-20190216800-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, DBH, CYP3A43 | SLC6A3 21/4885SLC6A2 31/4885CHRNA1 246/4885 |
| US-11433035-B2 | Dosage forms and methods for enantiomerically enriched or pure bupropion | CYP2D6, CYP3A5, CYP2B6 | SLC6A3 12/4885SLC6A2 7/4885CHRNA1 213/4885 |
| US-11786488-B2 | Dosage forms and methods for enantiomerically enriched or pure bupropion | CYP2D6, CYP3A5, CYP2B6 | SLC6A3 12/4885SLC6A2 7/4885CHRNA1 213/4885 |
| US-20240293342-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A5, GABBR1 | SLC6A3 12/4885SLC6A2 6/4885CHRNA1 208/4885 |
| US-20250228845-A1 | COMBINATION DOSAGE FORMS AND ADMINISTRATION THEREOF | CYP3A5, GABBR1, GABBR2 | SLC6A3 20/4885SLC6A2 13/4885CHRNA1 115/4885 |
| US-20190216801-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, DBH, CYP3A43 | SLC6A3 21/4885SLC6A2 31/4885CHRNA1 246/4885 |
| US-12102606-B2 | Dosage forms and methods for enantiomerically enriched or pure bupropion | CYP2D6, CYP3A5, CYP2B6 | SLC6A3 12/4885SLC6A2 7/4885CHRNA1 213/4885 |
| US-20220193011-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A5, CYP2B6 | SLC6A3 12/4885SLC6A2 7/4885CHRNA1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.